Quintiles has acquired pharmaceutical commercialization and marketing firm VCG & Associates and its subsidiary, VCG Bio, in a move to bolster the company’s drug capabilities to bring new drugs to market.
Durham, North Carolina based Quintiles, already the largest clinical research organization or CRO, has been taking steps to build its drug commercialization offerings in recent years. Quintiles already provides a sales force for drug companies looking to outsource that work. But Quintiles spokesman Phil Bridges said that the VCG acquisitions bring new experience in branding, market access and distribution.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“The addition of VCG allows us to strengthen our capabilities in that area,” Bridges said.
Privately held VCG & Associates was founded in 2003 and is based in Holliston, Massachusetts. VCG BIO operates from Cave Creek, Arizona. Financial terms of the transaction were not disclosed.
VCG & Associates works with small and medium-sized pharmaceutical companies that want to outsource their drug commercialization efforts, or companies that want to establish a commercial presence in the United States. VCG & Associates also works with drug development companies entering the market for the first time.
The company has launched more than 40 products in categories including ophthalmology, oncology, pain management and cardiovascular. VCG BIO provides consulting services to life science companies at all stages of a drug’s life cycle from product development to patent expiration.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
While VCG & Associates and VCG BIO tend to work with rising life science companies, Bridges said that the company has the capability to work with large pharmaceutical companies as well. As part of Quintiles’ Global Commercial Solutions group, the 25-employee VCG will have the opportunity to do so. Quintiles’ commercial unit has more than 10,000 employees in 30 countries.
